市場調査レポート

商品コード

1622408

非小細胞肺がんの市場規模、シェア、成長分析、タイプ別、治療法別、最終用途産業別、地域別 - 産業予測、2025～2032年

Non-Small Cell Lung Cancer Market Size, Share, Growth Analysis, By Type (Adenocarcinoma, Squamous Cell Carcinoma), By Treatment (Chemotherapy, Targeted Therapy), By End-Use Industry, By Region - Industry Forecast 2025-2032

出版日: 2024年12月21日
発行: SkyQuest
ページ情報: 英文 165 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 763,518円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 893,172円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,022,826円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
目次

概要

サンプル依頼リストに入れる

非小細胞肺がん市場規模は2023年に269億4,000万米ドルと評価され、2024年の306億8,000万米ドルから2032年には869億4,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは13.9%で成長する見通しです。

免疫チェックポイント阻害薬（ICI）のファーストライン治療へのイントロダクションが、非小細胞肺がん（NSCLC）分野の市場収益成長を大きく促進しています。世界の肺がん患者の80～85%を占めるNSCLCの有病率は、主要企業に革新的な治療法の開発と既存の選択肢の有効性向上に注力するよう促しています。この成長は、肺がんが世界のがん関連死の主要原因であるという評価も後押ししています。NSCLCの診断件数の増加は、先進国と新興国の両方における社会的認知度の向上と相まって、市場ダイナミクスをさらに増幅させています。さらに、NSCLC治療薬をパイプラインに組み入れるという主要市場プレイヤーのコミットメントと、研究開発への投資の高まりも、世界市場の拡大を促す重要な要因となっています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
市場の最近の動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 会社概要
- 製品ポートフォリオ分析
- セグメント別シェア分析
- 収益の前年比比較（2022-2024）

主要企業プロファイル

F. Hoffmann-La Roche Ltd.（Switzerland）
AstraZeneca（United Kingdom）
Bristol-Myers Squibb Company（United States）
Merck & Co., Inc.（United States）
Novartis AG（Switzerland）
Pfizer Inc.（United States）
Takeda Pharmaceutical Company Limited（Japan）
Bayer AG（Germany）
Eli Lilly and Company（United States）
GlaxoSmithKline plc（United Kingdom）
Sanofi（France）
AbbVie Inc.（United States）
Johnson & Johnson（United States）
Gilead Sciences, Inc.（United States）
Amgen Inc.（United States）
Boehringer Ingelheim GmbH（Germany）
Daiichi Sankyo Company, Limited（Japan）
Astellas Pharma Inc.（Japan）
Biogen Inc.（United States）
Regeneron Pharmaceuticals, Inc.（United States）

結論と推奨事項

Product Code: SQMIG25K2005

Non-Small Cell Lung Cancer Market size was valued at USD 26.94 Billion in 2023 and is poised to grow from USD 30.68 Billion in 2024 to USD 86.94 Billion by 2032, growing at a CAGR of 13.9% during the forecast period (2025-2032).

The introduction of immune checkpoint inhibitors (ICIs) for first-line treatment is significantly propelling market revenue growth in the non-small cell lung cancer (NSCLC) sector. Representing 80-85% of lung cancer cases globally, NSCLC's prevalence has prompted leading companies to focus on developing innovative therapies and enhancing the efficacy of existing options. This growth is also driven by lung cancer's reputation as a leading cause of cancer-related deaths worldwide. Rising diagnoses of NSCLC, coupled with increased public awareness in both developed and developing countries, are further amplifying market dynamics. Additionally, the commitment of major market players to incorporate NSCLC medications into their pipelines and their heightened investment in research and development are crucial factors driving the expansion of the global market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Non-Small Cell Lung Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Non-Small Cell Lung Cancer Market Segmental Analysis

Global Non-Small Cell Lung Cancer Market is segmented by type, treatment, end-use industry and region. Based on type, the market is segmented into adenocarcinoma, squamous cell carcinoma, large cell carcinoma and large cell neuroendocrine tumors. Based on treatment, the market is segmented into chemotherapy, targeted therapy, immunotherapy and others. Based on end-use industry, the market is segmented into hospitals, homecare, specialty clinics and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Non-Small Cell Lung Cancer Market

The Non-Small Cell Lung Cancer (NSCLC) market is primarily driven by the escalating incidence of lung cancer attributed to factors such as smoking, air pollution, and increased vulnerability due to HIV infection, alongside a growing population. Additionally, the market is expected to expand with the rising number of regulatory approvals for innovative therapies tailored to NSCLC. Key industry players are prioritizing research and development investments to address the surging demand for effective treatment options. This combination of increasing disease prevalence and advancements in drug approvals is poised to significantly enhance the growth trajectory of the NSCLC market in the upcoming years.

Restraints in the Non-Small Cell Lung Cancer Market

A significant challenge facing the non-small cell lung cancer market is the high cost associated with its treatment options. While effective therapies such as chemotherapy, surgery, targeted therapies, radiation, and immunotherapy are available, they come with substantial financial burdens. This expensive nature of treatment poses a barrier to accessing care, limiting affordability for many patients and ultimately restricting market growth. Consequently, the financial implications of these therapies can hinder the overall advancement of the non-small cell lung cancer market, making it difficult for a broader population to benefit from available treatment options.

Market Trends of the Non-Small Cell Lung Cancer Market

The non-small cell lung cancer (NSCLC) market is witnessing significant growth, driven by a rise in diagnoses and heightened awareness across global regions, both developed and developing. Innovative treatment options, including targeted therapies and immunotherapies, are being actively developed by leading pharmaceutical companies, expanding their portfolios. Increased investment in research and development from major players is enhancing treatment availability and efficacy, further stimulating market momentum. Additionally, supportive regulatory frameworks and healthcare initiatives are improving patient access to advanced therapies, positioning the NSCLC market for sustained growth in the coming years as it aligns with evolving medical needs and technological advancements.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Advancement

Global Non-Small Cell Lung Cancer Market Size by Type & CAGR (2025-2032)

Market Overview
Adenocarcinoma
Squamous Cell Carcinoma
Large Cell Carcinoma
Large Cell Neuroendocrine Tumors

Global Non-Small Cell Lung Cancer Market Size by Treatment & CAGR (2025-2032)

Market Overview
Chemotherapy
Targeted Therapy
- Bevacizumab
- Necitumumab
- Ramucirumab
Immunotherapy
- Nivolumab
- Atezolizumab
Others

Global Non-Small Cell Lung Cancer Market Size by End-Use Industry & CAGR (2025-2032)

Market Overview
Hospitals
Homecare
Specialty Clinics
Others

Global Non-Small Cell Lung Cancer Market Size & CAGR (2025-2032)

North America (Type, Treatment, End-Use Industry)
- US
- Canada
Europe (Type, Treatment, End-Use Industry)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Treatment, End-Use Industry)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Treatment, End-Use Industry)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Treatment, End-Use Industry)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

非小細胞肺がんの市場規模、シェア、成長分析、タイプ別、治療法別、最終用途産業別、地域別 - 産業予測、2025～2032年

Non-Small Cell Lung Cancer Market Size, Share, Growth Analysis, By Type (Adenocarcinoma, Squamous Cell Carcinoma), By Treatment (Chemotherapy, Targeted Therapy), By End-Use Industry, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

非小細胞肺がん市場規模：タイプ別

非小細胞肺がん市場規模：治療法別

非小細胞肺がん市場規模：最終用途産業別

非小細胞肺がん市場規模